Jonathan Chang
Stock Analyst at Leerink Partners
(4.12)
# 1,619
Out of 4,670 analysts
553
Total ratings
37.9%
Success rate
7.7%
Average return
Main Sectors:
Stocks Rated by Jonathan Chang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| WHWK Whitehawk Therapeutics | Initiated Coverage: Buy | $9 | $4.73 | +90.27% | 1 | Jul 13, 2026 | |
| MOLN Molecular Partners AG | Reiterated: Buy | n/a | $4.40 | - | 7 | Jun 2, 2026 | |
| CMPX Compass Therapeutics | Maintained: Buy | $11 | $2.40 | +358.33% | 1 | Apr 27, 2026 | |
| REPL Replimune Group | Downgraded: Hold | $13 → $2 | $14.77 | -86.46% | 48 | Apr 13, 2026 | |
| RVMD Revolution Medicines | Reiterated: Buy | $67 → $147 | $209.46 | -29.82% | 40 | Apr 13, 2026 | |
| NBTX Nanobiotix | Maintained: Buy | $24 → $37 | $43.55 | -15.04% | 17 | Apr 1, 2026 | |
| IMTX Immatics | Reiterated: Buy | $17 | $8.93 | +90.37% | 44 | Mar 6, 2026 | |
| AKTS Aktis Oncology | Initiated Coverage: Buy | $31 | $24.07 | +28.79% | 1 | Feb 3, 2026 | |
| NVCR NovoCure | Reiterated: Buy | $33 → $24 | $17.10 | +40.35% | 19 | Jan 13, 2026 | |
| KURA Kura Oncology | Reiterated: Buy | $20 | $11.89 | +68.21% | 51 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $74 | $26.01 | +184.51% | 51 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $34 → $39 | $33.45 | +16.59% | 45 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $8 → $6 | $1.96 | +206.12% | 36 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $8 → $5 | $4.10 | n/a | 38 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $0.11 → $0.09 | $0.027 | n/a | 38 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $24 | $4.37 | n/a | 30 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $60 | $36.88 | n/a | 13 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $27 | $27.80 | n/a | 32 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $2 | $0.0127 | n/a | 23 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $1,039.78 | n/a | 1 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $60.05 | n/a | 1 | Jan 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $18 → $2 | $0.0001 | n/a | 15 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $5.08 | n/a | 1 | Jun 1, 2022 |
Whitehawk Therapeutics
Jul 13, 2026
Initiated Coverage: Buy
Price Target: $9
Current: $4.73
Upside: +90.27%
Molecular Partners AG
Jun 2, 2026
Reiterated: Buy
Price Target: n/a
Current: $4.40
Upside: -
Compass Therapeutics
Apr 27, 2026
Maintained: Buy
Price Target: $11
Current: $2.40
Upside: +358.33%
Replimune Group
Apr 13, 2026
Downgraded: Hold
Price Target: $13 → $2
Current: $14.77
Upside: -86.46%
Revolution Medicines
Apr 13, 2026
Reiterated: Buy
Price Target: $67 → $147
Current: $209.46
Upside: -29.82%
Nanobiotix
Apr 1, 2026
Maintained: Buy
Price Target: $24 → $37
Current: $43.55
Upside: -15.04%
Immatics
Mar 6, 2026
Reiterated: Buy
Price Target: $17
Current: $8.93
Upside: +90.37%
Aktis Oncology
Feb 3, 2026
Initiated Coverage: Buy
Price Target: $31
Current: $24.07
Upside: +28.79%
NovoCure
Jan 13, 2026
Reiterated: Buy
Price Target: $33 → $24
Current: $17.10
Upside: +40.35%
Kura Oncology
Jan 13, 2026
Reiterated: Buy
Price Target: $20
Current: $11.89
Upside: +68.21%
Oct 21, 2025
Reiterated: Buy
Price Target: $74
Current: $26.01
Upside: +184.51%
Oct 13, 2025
Reiterated: Buy
Price Target: $34 → $39
Current: $33.45
Upside: +16.59%
Oct 10, 2025
Maintained: Hold
Price Target: $8 → $6
Current: $1.96
Upside: +206.12%
Aug 18, 2025
Maintained: Buy
Price Target: $8 → $5
Current: $4.10
Upside: n/a
Aug 13, 2025
Maintained: Hold
Price Target: $0.11 → $0.09
Current: $0.027
Upside: n/a
Aug 11, 2025
Reiterated: Buy
Price Target: $24
Current: $4.37
Upside: n/a
Aug 11, 2025
Maintained: Buy
Price Target: $60
Current: $36.88
Upside: n/a
Aug 7, 2025
Reiterated: Buy
Price Target: $27
Current: $27.80
Upside: n/a
Nov 12, 2024
Reiterated: Buy
Price Target: $2
Current: $0.0127
Upside: n/a
Jun 30, 2023
Maintained: Buy
Price Target: n/a
Current: $1,039.78
Upside: n/a
Jan 11, 2023
Rated: Buy
Price Target: n/a
Current: $60.05
Upside: n/a
Nov 14, 2022
Downgraded: Hold
Price Target: $18 → $2
Current: $0.0001
Upside: n/a
Jun 1, 2022
Maintained: Buy
Price Target: n/a
Current: $5.08
Upside: n/a